AVDL Avadel Pharmaceuticals Plc

Price (delayed)

$13.84

Market cap

$1.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.32

Enterprise value

$1.09B

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime ...

Highlights

The debt has declined by 21% year-on-year and by 12% since the previous quarter

The company's equity has shrunk by 169% YoY and by 80% QoQ

Avadel Pharmaceuticals's net income has plunged by 57% YoY and by 3.2% from the previous quarter

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.avadel.com

Peers: OCUP

Key stats

What are the main financial stats of AVDL

Market

Shares outstanding

76.77M

Market cap

$1.06B

Enterprise value

$1.09B

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$98.47M

EBITDA

-$96.65M

Free cash flow

-$67.21M

Per share

EPS

-$2.32

Free cash flow per share

-$1.05

Book value per share

-$0.59

Revenue per share

TBVPS

$1.94

Balance sheet

Total assets

$140.74M

Total liabilities

$178.91M

Debt

$115.16M

Equity

-$38.17M

Working capital

$30.11M

Liquidity

Debt to equity

-3.02

Current ratio

1.38

Quick ratio

1.27

Net debt/EBITDA

-0.33

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-98.3%

Return on equity

N/A

Return on invested capital

-73.5%

Return on capital employed

-160.4%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

AVDL stock price

How has the Avadel Pharmaceuticals stock price performed over time

Intraday

3.9%

1 week

-2.95%

1 month

37.85%

1 year

1,193.46%

YTD

93.3%

QTD

51.09%

Financial performance

How have Avadel Pharmaceuticals's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$98.23M

Net income

-$141.82M

Gross margin

N/A

Net margin

N/A

Avadel Pharmaceuticals's net income has plunged by 57% YoY and by 3.2% from the previous quarter

Growth

What is Avadel Pharmaceuticals's growth rate over time

Valuation

What is Avadel Pharmaceuticals stock price valuation

P/E

N/A

P/B

N/A

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Avadel Pharmaceuticals's EPS has shrunk by 51% YoY

The company's equity has shrunk by 169% YoY and by 80% QoQ

Efficiency

How efficient is Avadel Pharmaceuticals business performance

AVDL's return on assets has dropped by 176% year-on-year and by 18% since the previous quarter

The ROIC has plunged by 123% YoY and by 31% from the previous quarter

Dividends

What is AVDL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AVDL.

Financial health

How did Avadel Pharmaceuticals financials performed over time

The total assets is 21% less than the total liabilities

Avadel Pharmaceuticals's current ratio has plunged by 62% YoY and by 24% from the previous quarter

AVDL's quick ratio has dropped by 55% year-on-year and by 27% since the previous quarter

The company's equity has shrunk by 169% YoY and by 80% QoQ

Avadel Pharmaceuticals's debt to equity has soared by 51% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.